首页> 外文期刊>Tropical Animal Health and Production >Preparation and evaluation of chicken embryo-adapted fowl adenovirus serotype 4 vaccine in broiler chickens
【24h】

Preparation and evaluation of chicken embryo-adapted fowl adenovirus serotype 4 vaccine in broiler chickens

机译:肉鸡适应鸡胚的禽腺病毒4型血清疫苗的制备与评价

获取原文
获取原文并翻译 | 示例
       

摘要

The current study was planned to develop an efficient vaccine against hydropericardium syndrome virus (HSV). Currently, formalin-inactivated liver organ vaccines failed to protect the Pakistan broiler industry from this destructive disease of economic importance. A field isolate of the pathogenic hydropericardium syndrome virus was adapted to chicken embryos after four blind passages. The chicken embryo-adapted virus was further serially passaged (12 times) to get complete attenuation. Groups of broiler chickens free from maternal antibodies against HSV at the age of 14 days were immunized either with 16th passage attenuated HSV vaccine or commercially formalized liver organ vaccine. The antibody response, measured by enzyme-linked immunosorbent assay was significantly higher (P < 0.05) in the group immunized with the 16th passage attenuated HSV vaccine compared to the group immunized with liver organ vaccine at 7, 14, and 21 days post-immunization. At 24 days of age, the broiler chickens in each group were challenged with 103.83 embryo infectious dose50 of pathogenic HSV and were observed for 7 days post-challenge. Vaccination with the 16th passage attenuated HSV gave 94.73% protection as validated on the basis of clinical signs (5.26%), gross lesions in the liver and heart (5.26%), histopathological lesions in the liver (1.5 ± 0.20), and mortality (5.26%). The birds inoculated with liver organ vaccine showed significantly low (p < 0.05; 55%) protection estimated on the basis of clinical signs (40%), gross lesions in the liver and heart (45%), histopathological lesions in the liver (2.7 ± 0.72), and mortality (35%). Birds in the unvaccinated control group showed high morbidity (84%), mortality (70%), gross (85%), and histopathological lesions (3.79 ± 0.14) with only 10% protection. In conclusion, this newly developed HSV vaccine proved to be immunogenic and has potential for controlling HSV infections in chickens.
机译:目前的研究计划开发一种有效的抗心包积水综合征病毒(HSV)的疫苗。目前,福尔马林灭活的肝器官疫苗未能保护巴基斯坦肉鸡业免受这种具有重要经济意义的破坏性疾病的侵害。经过四个盲目传代后,将病原性水囊病综合症病毒的野外隔离株适应了鸡胚。将适应鸡胚的病毒进一步连续传代(12次)以获得完全减毒。用第16代减毒HSV疫苗或商业化的肝器官疫苗免疫14天龄无抗HSV母源抗体的肉鸡群。通过第16代减毒HSV疫苗免疫的组,用酶联免疫吸附法测定的抗体应答与在免疫后第7天,第14天和第21天用肝器官疫苗免疫的组相比,显着更高(P <0.05) 。在24日龄时,每组肉鸡均受到10 3.83 胚胎感染剂量 50 致病性HSV的攻击,并在攻击后7天进行观察。根据临床症状(5.26%),肝脏和心脏的总体病变(5.26%),肝脏的组织病理学病变(1.5±0.20)和死亡率(第16代减毒HSV疫苗)给予94.73%的保护5.26%)。根据临床体征(40%),肝脏和心脏的总体损害(45%),肝脏的组织病理学损害(2.7)估算,接种肝器官疫苗的鸟类显示出明显较低的防护(p <0.05; 55%) ±0.72)和死亡率(35%)。未接种疫苗的对照组的禽只显示出高发病率(84%),死亡率(70%),肉眼可见(85%)和组织病理学病变(3.79±0.14),仅提供1​​0%的保护。总之,这种新开发的HSV疫苗被证明具有免疫原性,并具有控制鸡HSV感染的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号